Journal Article
. 2000 Feb; 18(3):623-31.
doi: 10.1200/JCO.2000.18.3.623.

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial

P Bonomi 1 K Kim  D Fairclough  D Cella  J Kugler  E Rowinsky  M Jiroutek  D Johnson  
  • PMID: 10653877
  •     96 citations


Purpose: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide.

Patients And Methods: The study was carried out by a multi-institutional cooperative group in chemotherapy-naive stage IIIB to IV NSCLC patients randomized to receive paclitaxel plus cisplatin or etoposide plus cisplatin. Paclitaxel was administered at two different dose levels (135 mg/m(2) and 250 mg/m(2)), and etoposide was given at a dose of 100 mg/m(2) daily on days 1 to 3. Each regimen was repeated every 21 days and each included cisplatin (75 mg/m(2)).

Results: The characteristics of the 599 patients were well-balanced across the three treatment groups. Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048). Comparing survival for the two dose levels of paclitaxel revealed no significant difference. The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152). For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246). With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms. Quality of life (QOL) declined significantly over the 6 months. However, QOL scores were not significantly different among the regimens.

Conclusion: As a result of these observations, paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.

Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group.
H Ueoka, M Tanimoto, +12 authors, M Harada.
Br J Cancer, 2001 Jul 05; 85(1). PMID: 11437395    Free PMC article.
Effect of computer support on younger women with breast cancer.
D H Gustafson, R Hawkins, +8 authors, A Salner.
J Gen Intern Med, 2001 Aug 25; 16(7). PMID: 11520380    Free PMC article.
Highly Cited.
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
E Baldini, A Ardizzoni, +7 authors, Italian Lung Cancer Task Force.
Br J Cancer, 2001 Nov 27; 85(10). PMID: 11720427    Free PMC article.
Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
G L Plosker, M Hurst.
Pharmacoeconomics, 2001 Dec 12; 19(11). PMID: 11735678
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
A Clegg, D A Scott, +2 authors, N Waugh.
Thorax, 2002 Jan 26; 57(1). PMID: 11809985    Free PMC article.
Systematic Review.
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.
C M Moinpour, B Lyons, +7 authors, D R Gandara.
Qual Life Res, 2002 May 23; 11(2). PMID: 12018735
Advanced non-small cell lung cancer.
M J Edelman, S L Khanwani.
Curr Treat Options Oncol, 2002 Jun 12; 2(1). PMID: 12057140
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
J S Waters, M E R O'Brien.
Br J Cancer, 2002 Aug 22; 87(5). PMID: 12189541    Free PMC article.
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study.
S Niho, K Kubota, +4 authors, Yutaka Nishiwaki.
Br J Cancer, 2002 Nov 28; 87(12). PMID: 12454762    Free PMC article.
Solitary sites of metastatic disease in non-small cell lung cancer.
Matthew J Schuchert, James D Luketich.
Curr Treat Options Oncol, 2003 Jan 15; 4(1). PMID: 12525281
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer.
S Negoro, N Masuda, +8 authors, CPT-11 Lung Cancer Study Group West.
Br J Cancer, 2003 Feb 06; 88(3). PMID: 12569373    Free PMC article.
Combination chemotherapy in the treatment of inoperable non-small cell lung cancer.
R M Rutherford, T Azher, J J Gilmartin.
Ir J Med Sci, 2003 Mar 22; 171(4). PMID: 12647906
Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.
M Cullen.
Thorax, 2003 Apr 02; 58(4). PMID: 12668803    Free PMC article.
Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.
Branislav Jeremic, Biljana Milicic, +2 authors, Nebojsa Nikolic.
J Cancer Res Clin Oncol, 2003 Apr 02; 129(2). PMID: 12669236
A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated.
Y-M Chen, R-P Perng, +4 authors, J Whang-Peng.
Br J Cancer, 2004 Jan 22; 90(2). PMID: 14735177    Free PMC article.
Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer.
H Katayama, H Ueoka, +10 authors, Y Hiraki.
Br J Cancer, 2004 Mar 05; 90(5). PMID: 14997193    Free PMC article.
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
P J Ross, S Ashley, +5 authors, M E R O'Brien.
Br J Cancer, 2004 May 13; 90(10). PMID: 15138470    Free PMC article.
Outcomes research in cancer clinical trial cooperative groups: the RTOG model.
D W Bruner, B Movsas, +5 authors, W Curran.
Qual Life Res, 2004 Aug 04; 13(6). PMID: 15287270
A less intensive combination of paclitaxel and carboplatin in advanced non-small cell lung cancer patients who have aged 60 years or more and has a poor performance status.
Young Joo Min, Jong Joon Ahn, +7 authors, Ki Man Lee.
Korean J Intern Med, 2004 Sep 16; 19(2). PMID: 15366642    Free PMC article.
Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
Perran F Yumuk, Nazim S Turhal, +6 authors, Rengin Ahiskali.
BMC Cancer, 2005 Jan 26; 5. PMID: 15667664    Free PMC article.
Lung cancer.
Irfan Maghfoor, Michael C Perry.
Ann Saudi Med, 2005 Apr 13; 25(1). PMID: 15822487    Free PMC article.
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
F Cappuzzo, S Novello, +11 authors, L Crinò.
Br J Cancer, 2005 Jun 16; 93(1). PMID: 15956971    Free PMC article.
Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial.
G P Stathopoulos, J Dimitroulis, +7 authors, J Stathopoulos.
Br J Cancer, 2005 Oct 28; 93(10). PMID: 16251879    Free PMC article.
Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Se Hoon Park, Seong Hwan Jeong, +8 authors, Jae Hoon Lee.
Med Oncol, 2005 Nov 02; 22(4). PMID: 16260853
Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.
Akihiko Gemma, Cai Li, +13 authors, Shoji Kudoh.
BMC Cancer, 2006 Jul 04; 6. PMID: 16813650    Free PMC article.
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
Christopher G Azzoli, Lee M Krug, +12 authors, Charles M Rudin.
J Thorac Oncol, 2007 Jul 04; 2(7). PMID: 17607120    Free PMC article.
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Alessandro Passardi, Lorenzo Cecconetto, +9 authors, Dino Amadori.
J Transl Med, 2008 Nov 04; 6. PMID: 18976450    Free PMC article.
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
Thomas E Stinchcombe, Ann M Mauer, +5 authors, Cancer and Leukemia Group B.
J Thorac Oncol, 2008 Nov 04; 3(11). PMID: 18978566    Free PMC article.
Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Ali Osman Kaya, Suleyman Buyukberber, +11 authors, Anatolian Society of Medical Oncology (ASMO).
Med Oncol, 2009 Feb 27; 27(1). PMID: 19242825
NSCLC in the elderly--the legacy of therapeutic neglect.
Jared Weiss, Corey Langer.
Curr Treat Options Oncol, 2009 May 19; 10(3-4). PMID: 19449105
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.
Irma Airoldi, Emma Di Carlo, +12 authors, Vito Pistoia.
PLoS One, 2009 Jul 08; 4(7). PMID: 19582164    Free PMC article.
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02.
Masatsugu Nakagawa, Tsutomu Nishimura, +6 authors, Masanori Fukushima.
BMC Res Notes, 2009 Aug 07; 2. PMID: 19656374    Free PMC article.
Optimizing the management of advanced non-small-cell lung cancer: a personal view.
M D Vincent.
Curr Oncol, 2009 Aug 13; 16(4). PMID: 19672420    Free PMC article.
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
Isao Oze, Katsuyuki Hotta, +5 authors, Mitsune Tanimoto.
PLoS One, 2009 Nov 17; 4(11). PMID: 19915681    Free PMC article.
A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.
Jong-Sung Park, Chang-Min Lee, +5 authors, Hyo-Jin Kim.
Cancer Res Treat, 2004 Feb 01; 36(1). PMID: 20396567    Free PMC article.
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
Noriyuki Masuda, Shunichi Negoro, +8 authors, Masahiro Fukuoka.
Cancer Chemother Pharmacol, 2010 May 18; 67(3). PMID: 20473611    Free PMC article.
Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer.
David J Stewart, Carmen Behrens, Jack Roth, Ignacio I Wistuba.
Lung Cancer, 2010 Jul 16; 71(2). PMID: 20627364    Free PMC article.
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Andrea Wang-Gillam, Susanne M Arnold, +5 authors, A Craig Lockhart.
Invest New Drugs, 2010 Aug 11; 30(1). PMID: 20697774
Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Chenguang Li, Yihua Sun, +3 authors, Haiquan Chen.
Lung, 2010 Aug 13; 188(5). PMID: 20703493
Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.
Allison R Baer, Chelsey A Kelly, +2 authors, Douglas W Blayney.
J Oncol Pract, 2010 Sep 03; 6(3). PMID: 20808551    Free PMC article.
Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer.
Leslie G Walker, Jennifer M Eremin, +14 authors, Oleg Eremin.
BMC Cancer, 2011 May 20; 11. PMID: 21592370    Free PMC article.
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Vega Iranzo, Rafael Sirera, +13 authors, Carlos Camps.
Clin Transl Oncol, 2011 Jun 18; 13(6). PMID: 21680302
Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients.
Koen Pardon, R Deschepper, +9 authors, EOLIC-consortium.
Support Care Cancer, 2012 Jan 17; 20(10). PMID: 22246616
Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.
Tien Hoang, Suzanne E Dahlberg, +4 authors, David H Johnson.
J Clin Oncol, 2012 Jan 25; 30(6). PMID: 22271472    Free PMC article.
[A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced non-small cell lung cancer in elderly patients].
Xiaomei Zeng, Zhixi Li, Mei Hou.
Zhongguo Fei Ai Za Zhi, 2012 Feb 18; 15(2). PMID: 22336235    Free PMC article.
Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.
Shinichi Toyooka, Katsuyuki Kiura, +5 authors, Hiroshi Date.
Interact Cardiovasc Thorac Surg, 2012 Feb 23; 14(5). PMID: 22354091    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI).
Naoya Hida, Hiroaki Okamoto, +6 authors, Koshiro Watanabe.
Cancer Chemother Pharmacol, 2012 May 09; 69(6). PMID: 22565592    Free PMC article.
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Youngjoo Lee, Sun Hye Kim, +3 authors, Jin Soo Lee.
J Cancer Res Clin Oncol, 2012 Jul 10; 138(12). PMID: 22772951
Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.
Edward B Garon.
Lung Cancer, 2012 Jul 17; 77(3). PMID: 22795702    Free PMC article.
The role of taxanes in the management of gastroesphageal cancer.
Paola Jimenez, Aditya Pathak, Alexandria T Phan.
J Gastrointest Oncol, 2012 Jul 20; 2(4). PMID: 22811858    Free PMC article.
Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
Tien Hoang, Suzanne E Dahlberg, +3 authors, David H Johnson.
J Thorac Oncol, 2012 Jul 31; 7(9). PMID: 22843087    Free PMC article.
Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials.
Ayako Matsuda, Kazue Yamaoka, Toshiro Tango.
Exp Ther Med, 2012 Sep 13; 3(1). PMID: 22969858    Free PMC article.
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Patricia M M B Soetekouw, Johanna N H Timmer-Bonte, +5 authors, Vivianne C G Tjan-Heijnen.
Int J Clin Oncol, 2012 Sep 27; 18(6). PMID: 23011101
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Yan Huang, Yunpeng Liu, +20 authors, Li Zhang.
Zhongguo Fei Ai Za Zhi, 2012 Oct 19; 15(10). PMID: 23075681    Free PMC article.
Anticancer drug clustering based on proteomic profiles and a sensitivity database in a lung cancer cell line panel.
Mitsunori Hino, Kuniko Matsuda, +12 authors, Akihiko Gemma.
Exp Ther Med, 2010 Jan 01; 1(1). PMID: 23136590    Free PMC article.
COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.
Corinne M Doll, Kathryn Winter, +6 authors, Anthony M Magliocco.
Int J Gynecol Cancer, 2012 Dec 12; 23(1). PMID: 23221733    Free PMC article.
Dynamics of tumor hypoxia in response to patupilone and ionizing radiation.
Katrin Orlowski, Carla Rohrer Bley, +5 authors, Martin Pruschy.
PLoS One, 2012 Dec 20; 7(12). PMID: 23251549    Free PMC article.
Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung.
Elizabeth A Handorf, Sean McElligott, +4 authors, David A Asch.
J Oncol Pract, 2013 Jan 02; 8(5). PMID: 23277762    Free PMC article.
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Tien Hoang, Suzanne E Dahlberg, Joan H Schiller, David H Johnson.
Lung Cancer, 2013 Apr 25; 81(1). PMID: 23611404    Free PMC article.
The microtubule stabilizer patupilone counteracts ionizing radiation-induced matrix metalloproteinase activity and tumor cell invasion.
Polina Furmanova-Hollenstein, Angela Broggini-Tenzer, +2 authors, Martin Pruschy.
Radiat Oncol, 2013 May 02; 8. PMID: 23631818    Free PMC article.
Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer.
Faruk Tas, Fatma Sen, +2 authors, Hakan Camlica.
Oncol Lett, 2013 Jun 14; 5(5). PMID: 23761836    Free PMC article.
Targeted therapy for non-small-cell lung cancer: past, present and future.
Patrick M Forde, David S Ettinger.
Expert Rev Anticancer Ther, 2013 Jun 19; 13(6). PMID: 23773106    Free PMC article.
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
G H Lyman, D C Dale, +5 authors, J Crawford.
Ann Oncol, 2013 Jun 22; 24(10). PMID: 23788754    Free PMC article.
Systematic Review.
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.
Suzanne E Dahlberg, Joan H Schiller, +4 authors, David H Johnson.
J Thorac Oncol, 2013 Jul 28; 8(9). PMID: 23887169    Free PMC article.
Mycelial Extract of Phellinus linteus Induces Cell Death in A549 Lung Cancer Cells and Elevation of Nitric Oxide in Raw 264.7 Macrophage Cells.
Jong-Jin Lee, Ho-Kyun Kwon, +4 authors, Jong-Lae Kim.
Mycobiology, 2006 Sep 01; 34(3). PMID: 24039488    Free PMC article.
Treatment of non-small cell lung cancer (NSCLC).
Konstantinos Zarogoulidis, Paul Zarogoulidis, +8 authors, Dionysios Spyratos.
J Thorac Dis, 2013 Oct 09; 5 Suppl 4. PMID: 24102012    Free PMC article.
Highly Cited. Review.
Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway.
Yi Lin, Jianping Xu, +2 authors, Lei Pan.
Tumour Biol, 2013 Nov 26; 35(4). PMID: 24272201
The Lake Wobegon effect: are all cancer patients above average?
Jacqueline H Wolf, Kevin S Wolf.
Milbank Q, 2013 Dec 11; 91(4). PMID: 24320166    Free PMC article.
Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.
Eileen Mannion, J J Gilmartin, +2 authors, Dympna Waldron.
Support Care Cancer, 2014 Feb 25; 22(5). PMID: 24563068
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Rafael Santana-Davila, Aniko Szabo, +3 authors, Jeff Whittle.
J Thorac Oncol, 2014 Mar 26; 9(5). PMID: 24662458    Free PMC article.
What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer.
Celia M Bridges, Ellen M Lavoie Smith.
Support Care Cancer, 2014 Jun 22; 22(9). PMID: 24952242
Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel).
Normand Blais, Vera Hirsh.
Front Oncol, 2014 Aug 08; 4. PMID: 25101242    Free PMC article.
Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations.
Ahmet Yilmaz, Nehad Mohamed, +9 authors, Weiqiang Zhao.
Int J Environ Res Public Health, 2014 Sep 16; 11(9). PMID: 25222473    Free PMC article.
Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.
M A Socinski.
Curr Oncol, 2014 Oct 11; 21(5). PMID: 25302040    Free PMC article.
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Morena Fasano, Carminia Maria Della Corte, +2 authors, Floriana Morgillo.
J Thorac Oncol, 2015 Jun 04; 10(8). PMID: 26039012    Free PMC article.
Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy.
Constantin Volovat, Igor M Bondarenko, +4 authors, Udo Müller.
Springerplus, 2015 Jul 15; 4. PMID: 26155455    Free PMC article.
Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.
Jing Yu, Jing Xiao, Yifan Yang, Bangwei Cao.
Medicine (Baltimore), 2015 Jul 15; 94(27). PMID: 26166081    Free PMC article.
The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical populations.
Elizabeth A Hahn, Jennifer L Beaumont, +4 authors, David Cella.
J Clin Epidemiol, 2016 Mar 05; 73. PMID: 26931288    Free PMC article.
Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study.
Mangesh P Kamath, K C Lakshmaiah, +3 authors, Suresh Mc Babu.
Lung India, 2016 Apr 07; 33(2). PMID: 27051102    Free PMC article.
Costunolide induces G1/S phase arrest and activates mitochondrial-mediated apoptotic pathways in SK-MES 1 human lung squamous carcinoma cells.
Peiyan Hua, Guangxin Zhang, +5 authors, Xingyi Zhang.
Oncol Lett, 2016 Apr 14; 11(4). PMID: 27073552    Free PMC article.
Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.
Rudi Bao, Pokman Chan.
J Exp Pharmacol, 2011 Jan 01; 3. PMID: 27186107    Free PMC article.
High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population.
Elmer E van Eeghen, Sandra D Bakker, Aart van Bochove, Ruud J L F Loffeld.
Int Sch Res Notices, 2015 Jan 01; 2015. PMID: 27347548    Free PMC article.
Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Fatma Sen, Makbule Tambas, +11 authors, Yesim Eralp.
Medicine (Baltimore), 2016 Jul 30; 95(30). PMID: 27472701    Free PMC article.
Factors affecting the quality of life of cancer patients undergoing chemotherapy: A questionnaire study.
Sema Üstündağ, Ayten Demir Zencirci.
Asia Pac J Oncol Nurs, 2015 Jan 01; 2(1). PMID: 27981088    Free PMC article.
Refining the treatment of advanced nonsmall cell lung cancer.
Shin Ogita, Antoinette J Wozniak.
Lung Cancer (Auckl), 2010 May 03; 1. PMID: 28210103    Free PMC article.
A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01).
Michio Nakamura, Atsushi Ishiguro, +17 authors, Yoshito Komatsu.
Oncologist, 2017 Mar 28; 22(5). PMID: 28341762    Free PMC article.
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
Charu Aggarwal, Hossein Borghaei.
Oncologist, 2017 Apr 15; 22(6). PMID: 28408617    Free PMC article.
Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment.
Alexander Lorz, Dana-Adriana Botesteanu, Doron Levy.
Front Oncol, 2017 Sep 16; 7. PMID: 28913178    Free PMC article.
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.
Wolfgang Schuette, Claus-Peter Schneider, +6 authors, Martin Reck.
Lung Cancer (Auckl), 2017 Nov 22; 8. PMID: 29158696    Free PMC article.
Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study.
Domitille Dano, Clémence Hénon, +13 authors, Audrey Monneur.
J Glob Oncol, 2019 Jul 20; 5. PMID: 31322991    Free PMC article.
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Yoshihiro Hattori, Yuko Kono, +11 authors, Miyako Satouchi.
BMC Cancer, 2020 Feb 13; 20(1). PMID: 32046667    Free PMC article.
Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy.
Lonny Yarmus, Christopher Mallow, +9 authors, Momen M Wahidi.
Chest, 2019 Feb 19; 156(3). PMID: 30776363    Free PMC article.
Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non-Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial.
Jie Liu, Jun J Mao, Susan Qing Li, Hongsheng Lin.
Integr Cancer Ther, 2020 Aug 26; 19. PMID: 32840126    Free PMC article.
Cancer symptom response as an oncology clinical trial end point.
Laura C Bouchard, Neil Aaronson, Kathleen Gondek, David Cella.
Expert Rev Qual Life Cancer Care, 2018 Jan 01; 3(2-3). PMID: 31020045    Free PMC article.
The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer.
Chenyang Zhao, Fengli Wang, +5 authors, Lujin Li.
Eur J Clin Pharmacol, 2021 Mar 30; 77(5). PMID: 33779768